Loading…
Beam Therapeutics Inc. is projected to rise to $36.52 by 2027, a +12% move from its current price of $32.68. BEAM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $31.46 | $32.70 | $34.00 | +0.07% |
| Jul 13 | $30.98 | $32.72 | $34.57 | +0.13% |
| Jul 14 | $30.62 | $32.75 | $35.02 | +0.20% |
| Jul 15 | $30.32 | $32.77 | $35.41 | +0.27% |
| Jul 16 | $30.07 | $32.79 | $35.76 | +0.34% |
| Jul 17 | $29.84 | $32.81 | $36.08 | +0.40% |
| Jul 18 | $29.63 | $32.83 | $36.38 | +0.47% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $29.63 | $32.83 | $36.38 | +0.47% |
| Week 2 | $28.53 | $32.99 | $38.14 | +0.95% |
| Week 3 | $27.75 | $33.14 | $39.59 | +1.42% |
| Week 4 | $27.12 | $33.30 | $40.89 | +1.90% |
| Week 5 | $26.60 | $33.46 | $42.09 | +2.38% |
| Week 6 | $26.15 | $33.62 | $43.22 | +2.86% |
| Week 7 | $25.74 | $33.77 | $44.31 | +3.35% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Beam Therapeutics Inc. is a biotechnology company that engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.
The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs, and BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. Beam has research collaboration agreements with Pfizer Inc., Verve Therapeutics, Inc., and Orbital Therapeutics. Beam Therapeutics Inc.
was incorporated in 2017 and is based in Cambridge, Massachusetts.
Beam Therapeutics Inc. trades as BEAM in the Healthcare space and currently sits with a price of $32.68 and a market capitalization of $3.36B, ranking 1665 by market size. The current price and market position reflect a stock that is monitored by investors in the context of its multiple precision genetic medicine programs and collaboration activity.
The long-term price outlook is bullish, with year-by-year targets showing meaningful upside from 2026 through 2050, including substantial gains by 2030, 2040, and 2050 alongside a wide implied range.
A major floor 33.0% below — a decisive break under it would weaken the trend.
The nearest floor, 11.4% below — buyers have tended to step in here.
The nearest ceiling, 16.0% above — a clean break opens room to run.
A major ceiling 29.0% above — clearing it would confirm fresh momentum.
Key BEAM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BEAM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $35.72 | Sell | $34.90 | Sell |
| MA 10 | $35.10 | Sell | $34.82 | Sell |
| MA 20 | $33.74 | Sell | $33.92 | Sell |
| MA 50 | $31.57 | Buy | $31.97 | Buy |
| MA 100 | $29.33 | Buy | $30.21 | Buy |
| MA 200 | $27.93 | Buy | $28.13 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.94 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -40.21 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.07 | Sell |
| ROC (12) | -1.57 | Sell |
| Bollinger %B (20,2) | 0.38 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.59 | Buy |
| Awesome (5,34) | 3.37 | Buy |
| Ultimate (7,14,28) | 44.24 | Neutral |
| Momentum (10) | -1.25 | Sell |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 36.05 | Sell |
| ADX (14) | 16.04 | Neutral |
| ATR (14) | 1.25 | Info |
The 30-day technical picture shows bullish tilt with RSI(14) at 50 and trend support near the market price. The 50-day simple moving average stands at $31.57, while the 200-day simple moving average is $27.93, signaling an ongoing positive drift. Near-term support is identified at $28.96 and resistance at $37.92, indicating a defined trading range around the current level.
The 30-day range spans from $25.31 to $42.20, illustrating the near-term volatility and potential for movement within that band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $21.90 | $32.68 | $48.63 | 0% | Neutral | |
| $27.94 | $36.52 | $51.13 | +12% | Neutral | |
| $32.41 | $44.16 | $64.96 | +35% | Bullish | |
| $35.31 | $49.82 | $76.15 | +52% | Bullish | |
| $43.79 | $63.74 | $100.58 | +95% | Bullish | |
| $53.51 | $80.15 | $130.04 | +145% | Bullish | |
| $51.33 | $78.98 | $131.34 | +142% | Bullish | |
| $54.29 | $85.68 | $145.70 | +162% | Bullish | |
| $57.77 | $93.44 | $162.16 | +186% | Bullish | |
| $55.11 | $91.26 | $161.38 | +179% | Bullish | |
| $80.95 | $149.63 | $286.09 | +358% | Bullish | |
| $169.51 | $376.68 | $805.26 | +10.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $21.90 | $32.68 | $41.05 | +0.00% |
| August 2026 | $29.23 | $34.90 | $43.08 | +6.79% |
| September 2026 | $28.81 | $34.75 | $43.55 | -0.44% |
| October 2026 | $29.80 | $36.26 | $46.04 | +4.36% |
| November 2026 | $31.04 | $38.04 | $48.82 | +4.91% |
| December 2026 | $30.40 | $37.51 | $48.63 | -1.38% |
Click any year to see its month-by-month BEAM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The BEAM price prediction for 2026 points to an average of $32.68 (low $21.90, high $48.63) — a potential gain of 0% on today's $32.68. Price action looks broadly range-bound.
In 2027, BEAM is projected to trade between $27.94 and $51.13, averaging $36.52 — a potential gain of +12% from today's $32.68. That is up +12% on the projected 2026 average. A consolidation phase looks the most probable path here.
Beam Therapeutics Inc.'s 2028 outlook centres on $44.16, within a $32.41 to $64.96 range. That is up +21% on the projected 2027 average. That marks a +35% change versus current levels. Momentum favours further upside here.
By 2029, BEAM could reach as high as $76.15, with a base case around $49.82 and support toward $35.31 — roughly +52% from $32.68. Buyers look set to stay in control over this stretch.
Expect BEAM to range from $43.79 to $100.58 through 2030. The $63.74 average target implies a +95% move from current prices. That is up +28% on the projected 2029 average. Momentum favours further upside here.
The BEAM price prediction for 2031 points to an average of $80.15 (low $53.51, high $130.04) — a potential gain of +145% on today's $32.68. Buyers look set to stay in control over this stretch.
In 2032, BEAM is projected to trade between $51.33 and $131.34, averaging $78.98 — a potential gain of +142% from today's $32.68. That is -1% versus the projected 2031 average. Momentum favours further upside here.
Beam Therapeutics Inc.'s 2033 outlook centres on $85.68, within a $54.29 to $145.70 range. That is up +8% on the projected 2032 average. That marks a +162% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, BEAM could reach as high as $162.16, with a base case around $93.44 and support toward $57.77 — roughly +186% from $32.68. Momentum favours further upside here.
Expect BEAM to range from $55.11 to $161.38 through 2035. The $91.26 average target implies a +179% move from current prices. That is -2% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
The BEAM price prediction for 2040 points to an average of $149.63 (low $80.95, high $286.09) — a potential gain of +358% on today's $32.68. Momentum favours further upside here.
In 2050, BEAM is projected to trade between $169.51 and $805.26, averaging $376.68 — a potential gain of +10.5x from today's $32.68. That is up +152% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in BEAM today (≈ 30.599755 BEAM) could be worth
$11,526.34
+$10,526.34 (+1053%) by 2050 · US Dollar
Based on the average projected BEAM price of $376.68 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BEAMwould be worth at today's price.
$1,000 invested in BEAM on Jul 10, 2025 (≈ 45.392645 BEAM) would be worth
$1,483.43
+$483.43 (+48.3%) today · 1.48× · US Dollar
Based on a BEAM entry price of $22.03 vs. today's $32.68.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $34.79 | $939.35 | -6.1% |
| 1 month ago | $29.49 | $1,108.17 | +10.8% |
| 3 months ago | $27.43 | $1,191.4 | +19.1% |
| 6 months ago | $33.69 | $970.02 | -3.0% |
| 1 year ago | $22.03 | $1,483.43 | +48.3% |
| All time (5.0y) ago | $98.39 | $332.15 | -66.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BEAM forecast.
Our base-case forecast reaches $65.00 around 2031.
Implied market cap at $65.00: $6.69B
The multi-year forecast paints a bullish long-run path for BEAM, with the average price rising across key milestones and substantial upside potential. By 2030, the average forecast is $63.74 with a max of $100.58 and a min of $43.79, reflecting a 95% return on investment at the max end within the period. By 2040, the average forecast climbs to $149.63 with a max of $286.09 and a min of $80.95, showing a 357.9% ROI at the max.
Looking further to 2050, the average forecast reaches $376.68 with a max of $805.26 and a min of $169.51, corresponding to a 1052.6% ROI at the max. Across years, sentiment shifts to bullish in the later horizon, aligning with higher price targets and wider upside potential. These are estimates and not guarantees; they assume the stated inputs and conditions hold and should be weighed against inherent market and sector risks, including volatility which is reflected in the forecast ranges.
Tap a question to reveal the answer.
In 2030, the forecast shows min $43.79, avg $63.74, max $100.58 with ROI 95%. The sentiment is BULLISH.
The forecast shows a bullish long-term path with averages rising to $63.74 by 2030, $149.63 by 2040, and $376.68 by 2050, with ROI up to 1052.6% by 2050. However, there is uncertainty and volatility (annualized around 70%), so these are estimates, not guarantees.
Yes. The forecast for 2030 shows a max of $100.58, indicating BEAM could reach about $100.58 by 2030.
Current price is $32.68 and market cap is $3.36B.
For 2050, the forecast is min $169.51, avg $376.68, max $805.26 with ROI 1052.6% and sentiment BULLISH.
Beam Therapeutics Inc. Community Discussion
0Share your Beam Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.